No Data
No Data
Sangamo Therapeutics Analyst Ratings
H.C. Wainwright Maintains Sangamo Therapeutics(SGMO.US) With Buy Rating, Maintains Target Price $5
Sangamo Therapeutics Announces Second Quarter 2024 Conference Call and Webcast
Why Saia Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
Sangamo Rallies for Third Day in Wake of Positive Gene Therapy Results
Peering Into Sangamo Therapeutics's Recent Short Interest
No Data